- Home
- SNT vs BYSI Comparison
SNT vs BYSI Comparison
Compare SNT & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNT | BYSI |
|---|---|---|
| Founded | 1965 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 58.4M |
| IPO Year | 2023 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SNT | BYSI |
|---|---|---|
| Price | $3.08 | $1.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 28.4K | 19.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.57 | $0.98 |
| 52 Week High | $5.34 | $3.44 |
Technical Indicators
Market Signals| Indicator | SNT | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 37.15 | 65.18 |
| Support Level | $2.75 | $1.69 |
| Resistance Level | $4.49 | $1.81 |
| Average True Range (ATR) | 0.23 | 0.14 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 14.77 | 87.50 |
Price Performance
Historical ComparisonAbout SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.